Newsroom Articles

Advances in science and treatment are changing how severe hypertriglyceridemia (sHTG) is identified and managed. Here are four trends helping shape the future of care.

Ionis has been recognized as one of the San Diego Business Journal's Best Places to Work for the third consecutive year. This year, Ionis ranked #3 in the Large Company category, climbing three spots from #6 in 2025.

Explore Yajaira's journey with severe hypertriglyceridemia (sHTG), including the risks of high triglycerides, pancreatitis, and the importance of early awareness.

Explore Ionis' 2025 Corporate Responsibility Report — covering RNA-targeted medicine breakthroughs, ESG commitments, employee impact, and sustainability milestones.

March marks Amyloidosis Awareness Month. We sat down with Charles, an 88-year-old retired cardiologist from Massachusetts, who shared what it’s like to diagnose and treat heart disease for decades and then face a diagnosis himself. His experience with transthyretin amyloid cardiomyopathy (ATTR-CM) offers a unique perspective on this underrecognized condition.

2025 was a defining year for Ionis, hallmarked by our first two independent launches as a commercial stage biotech company. Now, Ionis is poised for another transformative year - at JPM 2026 we shared highlights from the past year and outlined key anticipated milestones.

Through their stories, families, advocates and experts paint a vivid picture of what life with Angelman syndrome looks like – the obstacles, the triumphs and the moments of strength that define their journeys. They share their experiences navigating the path to diagnosis, the hallmark signs and symptoms of AS and, most importantly, the incredible joy that their children with AS bring to their lives. 

Rick has experienced symptoms of FCS his entire life. He has been hospitalized more times than he can count with acute pancreatitis and describes it as the most pain he has ever been in. Despite these challenges, Rick is hopeful about the future for people living with this rare and severe disease and passionate about helping other people with FCS.

Recognizing our industry-leading scientific innovation and company culture, Science magazine ranked Ionis their #2 Top Employer in 2025.

In celebration of Brett Monia, Ph.D., recipient of the 2025 Oligonucleotide Therapeutics Society (OTS) Lifetime Achievement Award, colleagues and peers reflect on his extraordinary impact on science, leadership and patient care.

Hear Dr. Sam Tsimikas, SVP of Global Cardiovascular Development, share how Ionis is redefining cardiometabolic care.

Endpoints News honors Ionis’ Holly Kordasiewicz, Ph.D., SVP, Neurology for her leadership, scientific impact and commitment to advancing diversity in biopharma